Aurinia Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Business Address
#140, 14315 - 118 AVENUE, EDMONTON, A0, T5L 4S6
Mailing Address
#140, 14315 - 118 AVENUE, EDMONTON, A0, T5L 4S6
Phone
250-744-2487
Fiscal Year End
1231
EIN
981231763
Financial Overview
FY2025
$173.17M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
Material Events
8-K
Leadership Change
March 23, 2026
High Impact
- Aurinia Pharmaceuticals undergoes a major leadership shake-up with new CEO, COO, and CFO appointments.
- New CEO Kevin Tang, a seasoned biotech investor, will take no salary, bonuses, or equity, aligning his interests directly with shareholders.
Insider Trading
STRONG BUY
1 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.